We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 130.12 | 61 | 09:54:02 |
From Apr 2019 to Apr 2024
By Chelsey Dulaney
Merck & Co. said Monday that its experimental drug regimen to reduce nausea in patients receiving chemotherapy met its primary endpoint goal in a late-stage study.
The phase-three study combined Merck's injectable fosaprepitant dimeglumine, called Emend, with antivomiting medicines.
Merck said the regimen provided greater protection from nausea and vomiting after chemotherapy than other antivomiting medicines in the study. Side effects included fatigue and diarrhea.
Merck said it plans to submit its data to the Food and Drug Administration in the second half of the year.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
